Mirati To Present Updated Clinical Data at ESMO Congress 2023

/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development biotechnology company, today announced several...

Related Keywords

Valencia ,Carabobo ,Venezuela ,Spain ,Hospital Universitario ,Zulia ,Madrid ,Hossein Borghaei ,Marinac Garassino ,Luis Paz ,Keith Kerr ,Merediths Pelster ,Aparna Parikh ,Alan Sandler ,European Society Of Medical Oncology Congress ,Linkedin ,Exchange Commission ,Facebook ,Harvard Medical School ,Cancer Center ,Nasdaq ,Twitter ,Mirati Therapeutics Inc ,National Comprehensive Cancer Network ,Clinical Practice Guidelines ,Rectal Cancers ,Mirati Therapeutics ,European Society ,Medical Oncology Congress ,Proffered Paper ,Adagrasib With ,Without Cetuximab ,Patients With ,Mutated Colorectal Cancer ,Tumor Biomarkers ,Proffered Paper Session ,Sitravatinib Plus Nivolumab Versus Docetaxel ,New Horizons ,Luis Paz Ares ,Mass General Cancer Center ,Valencia Auditorium ,Nc ,